Literature DB >> 15919568

The relationship between naloxone dose and key patient variables in the treatment of non-fatal heroin overdose in the prehospital setting.

Kate Cantwell1, Paul Dietze, Louisa Flander.   

Abstract

OBJECTIVES: To examine the relationship between key patient variables and variation in naloxone dose (from the standard dose of 1.6 mg IMI) administered by ambulance paramedics in the prehospital management of heroin overdose.
METHODS: A retrospective analysis of 7985 ambulance patient care records of non-fatal heroin overdose cases collected in greater metropolitan Melbourne. The main outcome measure was the dose of intramuscular naloxone required to increase the level of consciousness and the respiratory rate in patients presenting with suspected heroin overdose. Key patient variables influencing the dose that were recorded included: age, sex, initial patient presentation and reported concurrent alcohol use.
RESULTS: Multinomial logistic regression revealed that patients with higher levels of consciousness and respiratory rates on arrival of the paramedic crew were more likely to receive a less than standard dose of naloxone. Conversely, patients with lower levels of consciousness and low respiratory rates received greater than standard doses of naloxone for resuscitation. Patients who received greater than the standard dose of naloxone were 2.25 (95% CI, 1.83-2.77) times more likely to have been under the influence of alcohol when consuming the heroin that resulted in overdose.
CONCLUSIONS: The concurrent use of alcohol with heroin resulted in the use of greater than standard doses of naloxone by paramedics in resuscitating overdose patients. It is possible that the higher dose of naloxone is required to reverse the combined effects of alcohol and heroin. There was also a link between initial patient presentation and the dose of naloxone required for resuscitation. In light of these findings, it would appear that initial patient presentation and evidence of alcohol use might be useful guides as to providing the most effective dose of naloxone in the prehospital setting.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15919568     DOI: 10.1016/j.resuscitation.2004.12.012

Source DB:  PubMed          Journal:  Resuscitation        ISSN: 0300-9572            Impact factor:   5.262


  7 in total

Review 1.  Naloxone dosage for opioid reversal: current evidence and clinical implications.

Authors:  Rachael Rzasa Lynn; J L Galinkin
Journal:  Ther Adv Drug Saf       Date:  2017-12-13

Review 2.  Review of naloxone safety for opioid overdose: practical considerations for new technology and expanded public access.

Authors:  Daniel P Wermeling
Journal:  Ther Adv Drug Saf       Date:  2015-02

3.  Use of Naloxone by Emergency Medical Services during Opioid Drug Overdose Resuscitation Efforts.

Authors:  Steven Allan Sumner; Melissa C Mercado-Crespo; M Bridget Spelke; Leonard Paulozzi; David E Sugerman; Susan D Hillis; Christina Stanley
Journal:  Prehosp Emerg Care       Date:  2015-09-18       Impact factor: 3.077

4.  Attitudes of Australian heroin users to peer distribution of naloxone for heroin overdose: perspectives on intranasal administration.

Authors:  Debra Kerr; Paul Dietze; Anne-Maree Kelly; Damien Jolley
Journal:  J Urban Health       Date:  2008-03-18       Impact factor: 3.671

5.  Factors associated with withdrawal symptoms and anger among people resuscitated from an opioid overdose by take-home naloxone: Exploratory mixed methods analysis.

Authors:  Joanne Neale; Nicola J Kalk; Stephen Parkin; Caral Brown; Laura Brandt; Aimee N C Campbell; Felipe Castillo; Jermaine D Jones; John Strang; Sandra D Comer
Journal:  J Subst Abuse Treat       Date:  2020-08-05

6.  Illicit opioid intoxication: diagnosis and treatment.

Authors:  A Fareed; S Stout; J Casarella; S Vayalapalli; J Cox; K Drexler
Journal:  Subst Abuse       Date:  2011-04-18

7.  Prehospital naloxone administration - what influences choice of dose and route of administration?

Authors:  Ida Tylleskar; Linn Gjersing; Lars Petter Bjørnsen; Anne-Cathrine Braarud; Fridtjof Heyerdahl; Ola Dale; Arne Kristian Skulberg
Journal:  BMC Emerg Med       Date:  2020-09-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.